RESMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.1 USD | +18.89% |
|
+21.92% | +26.76% |
| Sales 2024 * | 4.68B 375B | Sales 2025 * | 5.02B 402B | Capitalization | 32.03B 2,564B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.03B 82.13B | Net income 2025 * | 1.2B 96.22B | EV / Sales 2024 * | 6.95 x |
| Net Debt 2024 * | 501M 40.12B | Net cash position 2025 * | 375M 29.99B | EV / Sales 2025 * | 6.31 x |
| P/E ratio 2024 * |
31.3
x | P/E ratio 2025 * |
27.1
x | Employees | 10,140 |
| Yield 2024 * |
0.9% | Yield 2025 * |
0.98% | Free-Float | 77.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on ResMed, Inc.
More recommendations
More press releases
More news
| 1 day | +18.89% | ||
| 1 week | +21.92% | ||
| Current month | +10.11% | ||
| 1 month | +12.30% | ||
| 3 months | +14.68% | ||
| 6 months | +57.18% | ||
| Current year | +26.76% |
1 week
178.49
218.38
1 month
172.19218.38
Current year
164.12218.38
1 year
132.24243.52
3 years
132.24301.34
5 years
102.56301.34
10 years
45.74301.34
| Managers | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 31/08/00 |
Peter Farrell
FOU | Founder | 81 | 31/05/89 |
Brett Sandercock
DFI | Director of Finance/CFO | 57 | 31/12/97 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Mick Farrell
CEO | Chief Executive Officer | 51 | 31/08/00 |
Ron Taylor
BRD | Director/Board Member | 76 | 31/12/04 |
Peter Farrell
FOU | Founder | 81 | 31/05/89 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.09% | 18 M€ | +3.79% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 218.1 | +18.89% | 4,330,840 |
| 25/04/24 | 183.4 | -0.20% | 1,124,546 |
| 24/04/24 | 183.8 | -0.24% | 973,428 |
| 23/04/24 | 184.2 | +2.15% | 1,202,959 |
| 22/04/24 | 180.4 | +0.84% | 1,218,743 |
Delayed Quote Nyse, April 26, 2024 at 09:00 pm
More quotes
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
218.1
USD
Average target price
212.4
USD
Spread / Average Target
-2.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.76% | 32.03B | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| -12.18% | 19.47B |
- Stock Market
- Equities
- RMD Stock
